Biowaiver monographs for immediate release solid oral dosage forms: Aciclovir

Journal of Pharmaceutical Sciences

Volumn 97, Issue 12, 2008, Pages 5061-5073

  Arnal, J ^a   Gonzalez Alvarez, I ^a   Bermejo, M ^a   Amidon, G L ^b   Junginger, H E ^c   Kopp, S ^d   Midha, K K ^e   Shah, V P ^f   Stavchansky, S ^g   Dressman, J B ^h   Barends, D M ⁱ  

^a UNIVERSITY OF VALENCIA   (Spain)

^b UNIVERSITY OF MICHIGAN   (United States)

^c NARESUAN UNIVERSITY   (Thailand)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e UNIVERSITY OF SASKATCHEWAN   (Canada)

^f International Pharmaceutical Federation FIP   (Netherlands)

^g UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^h GOETHE UNIVERSITY   (Germany)

ⁱ NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Absorption; Aciclovir; Bioequivalence; Biopharmaceutics classification system (BCS); Permeability; Regulatory science; Solubility

Indexed keywords

ACERPES; ACICLOBETA; ACICLODAN; ACICLOVIR; ACTAVIS; ATTAPULGITE; CELLULOSE; CROSCARMELLOSE SODIUM; CROSPOVIDONE; DOCUSATE SODIUM; EDETATE SODIUM; EXCIPIENT; GEAVIR; GELATIN; HYDROXYPROPYLMETHYLCELLULOSE; LACTOSE; MACROGOL; MACROGOL 400; MAGNESIUM STEARATE; POLYSORBATE 80; POVIDONE; PROPYLENE GLYCOL; SILICON DIOXIDE; STARCH; STARCH GLYCOLATE SODIUM; STEARYL FUMARATE SODIUM; UNCLASSIFIED DRUG; VIRZIN; ZOVIR;

AREA UNDER THE CURVE; BIOEQUIVALENCE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; HUMAN; HUMAN CELL; IMMEDIATE DRUG RELEASE; NOTE; TABLET FORMULATION;

EID: 57349111826     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21392     Document Type: Article

References (76)

1. Vogelpoel H, Welink J, Amidon GL, Junginger HE, Midha KK, Moller H, Olling M, Shah VP, Barends DM. 2004. Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: Verapamil hydrochloride, propranolol hydrochloride, and atenolol. J Pharm Sci 93:1945-1956.
2. WHO. 2006. Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms. Technical Report Series, No937, 40th Report, Annex 8 of WHO Expert committee on specifications for pharmaceutical preparations. Available from URL http://whqlibdoc.who.int/trs/WHO_TRS_937_eng.pdf.
3. FDA. 2000. Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. Available from URL http://www.fda.gov/cder/guidance/ 3618fnl.pdf. ed.: U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER).
4. EMEA. 2001. Note for guidance on the investigation of bioavailability and bioequivalence. Available from URL http://www.emea.eu.int/pdfs/human/ewp/ 140198en.pdf. ed.: Committee for Proprietary Medicinal Products (CPMP).
5. Kalantzi L, Reppas C, Dressman JB, Amidon GL, Junginger HE, Midha KK, Shah VP, Stavchansky SA, Barends DM. 2006. Biowaiver monographs for immediate release solid oral dosage forms: Acetaminophen (paracetamol). J Pharm Sci 95:4-14.
6. Granero GE, Longhi MR, Becker C, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. Biowaiver monographs for immediate release solid oral dosage forms: Acetazolamide. J Pharm Sci (in press).
7. Manzo RH, Olivera ME, Amidon GL, Shah VP, Dressman JB, Barends DM. 2006. Biowaiver monographs for immediate release solid oral dosage forms: Amitriptyline hydrochloride. J Pharm Sci 95:966-973.
8. Verbeeck RK, Junginger HE, Midha KK, Shah VP, Barends DM. 2005. Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: Chloroquine phosphate, chloroquine sulfate, and chloroquine hydrochloride. J Pharm Sci 94:1389-1395.
9. Jantratid E, Prakongpan S, Dressman JB, Amidon GL, Junginger HE, Midha KK, Barends DM. 2006. Biowaiver monographs for immediate release solid oral dosage forms: Cimetidine. J Pharm Sci 95:974-984.
10. Becker C, Dressman JB, Amidon GL, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Barends DM. 2008. Biowaiver, monographs for immediate release solid oral dosage forms: Ethambutol dihydrochloride. J Pharm Sci 97:1350-1360.
11. Potthast H, Dressman JB, Junginger HE, Midha KK, Oeser H, Shah VP, Vogelpoel H, Barends DM. 2005. Biowaiver monographs for immediate release solid oral dosage forms: Ibuprofen. J Pharm Sci 94:2121-2131.
12. Becker C, Dressman JB, Amidon GL, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Barends DM. 2007. Biowaiver monographs for immediate release solid oral dosage forms: Isoniazid. J Pharm Sci 96:522-531.
13. Vogt M, Derendorf H, Kramer J, Junginger HE, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2007. Biowaiver monographs for immediate release solid oral dosage forms: Prednisolone. J Pharm Sci 96:27-37.
14. Vogt M, Derendorf H, Kramer J, Junginger HE, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2007. Biowaiver monographs for immediate release solid oral dosage forms: Prednisone. J Pharm Sci 96:1480-1489.
15. Becker C, Dressman JB, Junginger HE, Kopp S, Shah VP, Stavchansky S, Barends DM. Biowaiver, monographs for immediate release solid oral dosage forms: Pyrazinamide. J Pharm Sci (in press).
16. Kortejarvi H, Yliperttula M, Dressman JB, Junginger HE, Midha KK, Shah VP, Barends DM. 2005. Biowaiver monographs for immediate release solid oral dosage forms: Ranitidine hydrochloride. J Pharm Sci 94:1617-1625.
17. National Library of Medicine (NLM) and the National Institutes of Health, NCBI, 2006. PubMed. URL http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?otool= inlrivmlib.
18. Thomson Healthcare. Micromedex Healthcare Series. http://www.micromedex. com/products/hcs/.
19. World Health Organization, 2005. World Health Organization Model List of Essential Medicines. 15th ed. http://www.who.int/medicines/publications/ EssMedList15.pdf.
20. USP 27 - NF 22. 2006. The United States Pharmacopeia - The National Formulary. ed. The United States Pharmacopeial Convention Inc. Rockville MD: 2085.
21. European Pharmacopoeia 5th edition. ed. Strasbourg, France: Council of Europe, European Directorate for the Quality of Medicines.
22. Consejo General de Colegios Oficiales de Farmacéuticos 2005. Catálogo de Especialidades Farmacéuticas. pp 1316-1317.
23. AHFS Drug Information. 2004. American Society of Hospital Pharmacists (AHFS). Bethesda, MD. pp 765-775.
24. GlaxoSmithKline. 2003. Zovirax for injection. Product Information.
25. GlaxoSmithKline, 2005. Zovirax Prescribing Information.
26. WHOCC. 2006. WHO Collaborating Centre for Drug Statistics Methodology ATC index. ed.
27. O'Brien JJ, Campoli-Richards DM. 1989. Aciclovir: An updated review or its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 37:233-309.
28. Ellenhorn MJ. 1997. Medical toxicology. Diagnosis and treatment of human poisoning. 2nd subedition. Baltimore: Williams & Wilkins. pp 296-300.
29. Davenport A, Goel S, Mackenzie JC. 1992. Neurotoxicity of aciclovir in patients with end-stage renal failure treated with continuous ambulatory peritoneal dialysis. Am J Kidney Dis 20:647-649.
30. Da Conceicao M, Genco G, Favier JC, Verrot D, Pitti R. 1999. Toxicite cerebrale et renale de l'aciclovir chez un patient traite pour meningo-encephalite [Cerebral and renal toxicity of acyclovir in a patient treated for eningoencephalitis]. Ann Fr Anesth Reanim 18:996-999.
31. Eksborg S, Pal N, Kalin M, Palm C, Soderhall S. 2002. Pharmacokinetics of aciclovir in immunocompromized children with leukopenia and mucositis after chemotherapy: Can intravenous aciclovir be substituted by oral valaciclovir? Med Pediatr Oncol 38:240-246.
32. Landowski CP, Sun D, Foster DR, Menon SS, Barnett JL, Welage LS, Ramachandran C, Amidon GL. 2003. Gene expression in the human intestine and correlation with oral valaciclovir pharmacokinetic parameters. J Pharmacol Exp Ther 306:778-786.
33. Lycke J, Malmestrom C, Stahle L. 2003. Aciclovir levels in serum and cerebrospinal fluid after oral administration of valaciclovir. Antimicrob Agents Chemother 47:2438-2441.
34. MacDougall C, Guglielmo BJ. 2004. Pharmacokinetics of valaciclovir. J Antimicrob Chemother 53:899-901.
35. Soul-Lawton J, Seaber E, On N, Wootton R, Rolan P, Posner J. 1995. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of aciclovir, following oral administration to humans. Antimicrob Agents Chemother 39:2759-2764.
36. Steingrimsdottir H, Gruber A, Palm C, Grimfors G, Kalin M, Eksborg S. 2000. Bioavailability of aciclovir after oral administration of aciclovir and its prodrug valaciclovir to patients with leukopenia after chemotherapy. Antimicrob Agents Chemother 44:207-209.
37. Anand BS, Katragadda S, Mitra AK. 2004. Pharmacokinetics of novel dipeptide ester prodrugs of aciclovir after oral administration: Intestinal absorption and liver metabolism. J Pharmacol Exp Ther 311:659-667.
38. Thomsen AE, Christensen MS, Bagger MA, Steffansen B. 2004. Aciclovir prodrug for the intestinal di/tri-peptide transporter PEP T1:comparison of in vivo bioavailability in rats and transport in Caco-2 cells. Eur J Pharm Sci 23:319-325.
39. Tolle-Sander S, Lentz KA, Maeda DY, Coop A, Polli JE. 2004. Increased aciclovir oral bioavailability via a bile acid conjugate. Mol Pharm 1:40-48.
40. Hostetler KY, Parker S, Sridhar CN, Martin MJ, Li JL, Stuhmiller LM, van Wijk GM, van den Bosch H, Gardner MF, Aldern KA, Richman DD. 1993. Aciclovir diphosphate dimyristoylglycerol: A phospholipid prodrug with activity against aciclovir-resistant herpes simplex virus. Proc Natl Acad Sci USA 90:11835-11839.
41. Kristl A, Srcic S, Vrecer F, Sustar B, Vojnovic D. 1996. Polymorphism and pseudopolymorphism: Influencing the dissolution properties of the guanine derivative aciclovir. Int J Pharm 139:231-235.
42. British Pharmacopoeia. 2007. The Stationery Office on behalf of the Medicines and Healthcare products Regulatory Agency (MHRA).
43. Bergstrom CA, Norinder U, Luthman K, Artursson P. 2002. Experimental and computational screening models for prediction of aqueous drug solubility. Pharm Res 19:182-188.
44. Bergstrom CA, Strafford M, Lazorova L, Avdeef A, Luthman K, Artursson P. 2003. Absorption classification of oral drugs based on molecular surface properties. J Med Chem 46:558-570.
45. Kristl A. 1999. Estimation of aqueous solubility for some guanine derivatives using partition coefficient and melting temperature. J Pharm Sci 88:109-110.
46. Luengo J, Aranguiz T, Sepulveda J, Hernandez L, Von Plessing C. 2002. Preliminary pharmacokinetic study of different preparations of aciclovir with beta-cyclodextrin. J Pharm Sci 91:2593-2598.
47. Von Plessing Rossel C, Sepulveda Carreno J, Rodriguez-Baeza M, Bernabe Alderete J. 2000. Inclusion complex of the antiviral drug aciclovir with cyclodextrin in aqueous solution and in solid phase. Quim Nova 23:749-752.
48. Shojaei AH, Berner B, Xiaoling L. 1998. Transbuccal delivery of acyclovir. I. In vitro determination of routes of buccal transport. Pharm Res 15:1182-1188.
49. Kristl A, Pecar S, Kmetec V. 1999. Are calculated log P values for some guanine derivatives by different computer programs reliable? Int J Pharm 181:219-226.
50. Balon K, Riebesehl BU, Muller BW. 1999. Drug liposome partitioning as a tool for the prediction of human passive intestinal absorption. Pharm Res 16:882-888.
51. Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennernas H, Hussain AS, Junginger HE, Stavchansky SA, Midha KK, Shah VP, Amidon GL. 2004. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm 1:85-96.
52. FDA., 2007. Drugs@FDA: FDA approved drug products.
53. Salama NN, Scott KR, Eddington ND. 2004. DM27, an enaminone, modifies the in vitro transport of antiviral therapeutic agents. Biopharm Drug Dispos 25:227-236.
54. Yee S. 1997. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man-fact or myth. Pharm Res 14:763-766.
55. Alpha-Pharmaceuticals. 1999. Alpha Aciclovir data sheet.
56. Najib NM, Idkaidek N, Beshtawi M, Mohammed B, Admour I, Alam SM, Dham R. 2005. Bioequivalence assessment of Lovrak (Julphar, UAE) compared with Zovirax (Glaxo Wellcome, UK) - Two brands of Aciclovir - In healthy human volunteers. Biopharm Drug Dispos 26:7-12.
57. University of Texas Libraries. Clinical Pharmacology database. http://www.clinicalpharmacologyip.com.ezproxy.lib.utexas.edu/Forms/Monograph/ monograph.aspx?cpnumU8&secUmonphar, revision 9/28/2005.
58. Vergin H, Kikuta C, Mascher H, Metz R. 1995. Pharmacokinetics and bioavailability of different formulations of aciclovir. Arzneimittelforschung 45:508-515.
59. Yuen KH, Peh KK, Billa N, Chan KL, Toh WT. 1998. Bioavailability and pharmacokinetics of aciclovir tablet preparation. Drug Dev Ind Pharm 24:193-196.
60. Rojanasthien N, Teekachunhatean S, Kumsorn B, Chaichana N, Hay YK. 2002. Bioequivalence study of generic aciclovir compared with the brand name aciclovir. J Med Assoc Thai 85:1121-1129.
61. Al-Yamani MJ, Al-Khamis KI, El-Sayed YM, Bawazir SA, Al-Rashood KA, Gouda MW. 1998. Comparative bioavailability of two tablet formulations of aciclovir in healthy volunteers. Int J Clin Pharmacol Ther 36:222-226.
62. Bahrami G, Mirzaeei S, Kiani A. 2005. Determination of aciclovir in human serum by high-performance liquid chromatography using liquid-liquid extraction and its application in pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci 816:327-331.
63. FachInfo-Service, 2007. Arzneimittel-Informationen für Ärzte und Apotheker. Available at URL www.fachinfo.de.
64. Rege BD, Yu LX, Hussain AS, Polli JE. 2001. Effect of common excipients on Caco-2 transport of low-permeability drugs. J Pharm Sci 90:1776-1786.
65. FDA, 2007. Inactive Ingredients Database. Available at URL http://www.fda.gov/cder/iig/iigfaq-WEB.htm.
66. Gleiter CH, Klotz U, Kuhlmann J, Blume H, Stanislaus F, Harder S, Paulus H, Poethko-Muller C, Holz-Slomczyk M. 1998. When are bioavailability studies required? A German proposal. J Clin Pharmacol 38:904-911.
67. College ter Beoordeling van Geneesmiddelen. 2007. Lijst vrijstelling bio-equivalentieonderzoek (positieve lijst). Available at URL http://www.cbg-meb.nl/nl/reghoudr/vrij.htm.
68. Yu LX, Wang JT, Hussain AS. 2002. Evaluation of USP apparatus 3 for dissolution testing of immediate-release products. AAPS PharmSci 4:E1.
69. Lindenberg M, Kopp S, Dressman JB. 2004. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm 58:265-278.
70. Wu CY, Benet LZ. 2005. Predicting drug disposition via application of BCS: Transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22:11-23.
71. Polli JE, Yu LX, Cook JA, Amidon GL, Borchardt RT, Burnside BA, Burton PS, Chen ML, Conner DP, Faustino PJ, Hawi AA, Hussain AS, Joshi HN, Kwei G, Lee VH, Lesko LJ, Lipper RA, Loper AE, Nerurkar SG, Polli JW, Sanvordeker DR, Taneja R, Uppoor RS, Vattikonda CS, Wilding I, Zhang G. 2004. Summary workshop report: Biopharmaceutics classification system - Implementation challenges and extension opportunities. J Pharm Sci 93:1375-1381.
72. Blume HH, Schug BS. 1999. The biopharmaceutics classification system (BCS): Class III drugs - Better candidates for BA/BE waiver? Eur J Pharm Sci 9:117-121.
73. Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP, Shah VP, Lesko LJ, Chen ML, Lee VH, Hussain AS. 2002. Biopharmaceutics classification system: The scientific basis for biowaiver extensions. Pharm Res 19:921-925.
74. Yazdanian M, Glynn SL, Wright JL, Hawi A. 1998. Correlating partitioning and caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res 15:1490-1494.
75. Friedrichsen GM, Chen W, Begtrup M, Lee CP, Smith PL, Borchardt RT. 2002. Synthesis of analogs of L-valaciclovir and determination of their substrate activity for the oligopeptide transporter in Caco-2 cells. Eur J Pharm Sci 16:1-13.
76. de Vrueh RL, Smith PL, Lee CP. 1998. Transport of L-valine-aciclovir via the oligopeptide transporter in the human intestinal cell line, Caco-2. J Pharmacol Exp Ther 286:1166-1170.